Edwards Lifesciences Corporation
EW
$86.67
-$0.08-0.09%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 291.10M | 333.20M | 358.00M | 385.60M | -- |
| Total Depreciation and Amortization | 39.20M | 38.10M | 36.60M | 42.60M | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.70M | 89.20M | 7.90M | -92.60M | -- |
| Change in Net Operating Assets | 192.70M | -170.30M | -122.10M | -463.10M | -- |
| Cash from Operations | 573.70M | 290.20M | 280.40M | -127.50M | 351.80M |
| Capital Expenditure | -57.50M | -49.30M | -56.00M | -49.80M | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -298.20M | -- |
| Divestitures | -- | -- | -- | 0.00 | -- |
| Other Investing Activities | -370.30M | -122.80M | 141.30M | -228.70M | -- |
| Cash from Investing | -427.80M | -172.10M | 85.30M | -576.70M | 2.70B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 34.70M | 57.20M | 49.90M | 28.60M | -- |
| Repurchase of Common Stock | -538.70M | -5.50M | -308.60M | -100.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -236.10M | 1.00M | 700.00K | 100.00K | -- |
| Cash from Financing | -740.10M | 52.70M | -258.00M | 28.60M | -976.70M |
| Foreign Exchange rate Adjustments | -1.00M | -29.60M | -17.70M | 51.00M | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -595.20M | 141.20M | 90.00M | -624.60M | 2.03B |